Apr 11, 2002|
Ranbaxy: Making a global mark
Ranbaxy is expected to declare encouraging results for the quarter ended March'02. With US$ 750 m global revenues expected in the current year, it seems well on its way to become a billion dollar company by 2004. Collaborative marketing and research seem to be the new growth mantra for Ranbaxy.
(*- excl. extra-ordinary income on a standalone basis)
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Profit before Tax
|Profit after Tax/(Loss)
|Net profit margin (%)
|No. of Shares (eoy) (m)
|Diluted Earnings per share*
Ranbaxy is clearly leveraging the marketing infrastructure it has created over the years. During the last couple of months, the company has identified several joint marketing opportunities, especially in the overseas market. Apart from providing a boost to the revenues, these joint deals are slowly and steadily capturing a larger store shelf and consequently, higher bargaining power through wider product offerings for the overseas market.
Ranbaxy now has almost 50 approved products for the US markets, with 3 of its products logging US$ 10 m+ revenues last year. Apart from such collaborative marketing deals, Ranbaxy intends to enter into collaborative projects for biogenerics from a research and marketing perspective. It is also exploring alliance partnership opportunities in the OTC / herbal medicines segment. Ranbaxy intends to commit only a small portion of incremental investments in building manufacturing facilities. The company is now successfully creating intellectual properties banking on its brand and unlocking value from the marketing infrastructure it has struggled hard to create over the years. The international operations of the company has already achieved break-even last year with US$ 7m profits. This was mainly driven by the profitability of its US operations. The profit contribution from the international operations would rise as more subsidiaries achieve breakeven.
It may be recalled that the company recently received FDA approval for marketing Cefuroxime Axetil tablets in the US markets after a prolonged legal battle. Ceftum (generic Cefuroxime) is a molecule with a market size of US$ 400 m. Though the approval doesn’t ensure six-month marketing exclusivity for Ranbaxy, the only generic competitor (Apotex) is atleast 3-4 months behind. The market for the drug is expected to be a duopoly atleast for a year.
The company has already launched the drug at about 30% price discount to GSK's Ceftin. The company has issued a revenue guidance of US$ 50 m in FY02 from sales of this drug. Ranbaxy might record aggressive sales numbers from Cefuroxime in the current quarter on the back of stocking up by distributors. On a conservative basis we have assumed US$ 8.3 m revenues in the current quarter.
While sales is expected to improve by around 32%, PBT is likely to record a triple digit growth rate. Operating margins are expected to jump sharply on the back of high margin 'Ceftin' sales as also rising contribution of exports to total revenues. Exports are likely to contribute more than 58% to the total revenues of the company. Ranbaxy is also likely to record an extra-ordinary revenue of US$10 m, which it received as compensation from Eli Lilly for the termination of its strategic alliance for multi source generic products.
| Total Sales
On the research front, the 500 mg Cipro-D molecule licensed to Bayer AG has completed its clinical trials and Bayer has filed an NDA (New Drug Application). It may be noted that following approval from the authorities, it would reach the commercialisation stage. This could trigger a considerable milestone payment for Ranbaxy. Considering the time taken by regulatory authorities for approval we expect launch of Cipro-D by mid-2003, ahead of original Ciprofloxacin patent expiry in 2003 end. There is also a possibility of licensing deal for its BPH molecule, RBX-2258 (Phase II in India) in the current quarter given that the company is in advanced negotiations stage with several MNCs. However, on a conservative basis, we have not factored in any revenues from outlicensing deal.
On a consolidated basis, we expect Ranbaxy to log an EPS of Rs 35.4 for the current year (FY03). At the current market price of Rs 870, the stock trades at 25x its FY03 (Dec'02) and 22x its FY04 (Dec'03) earnings expectations.
|Consolidated EPS (Rs.)
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
Aug 16, 2017
The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks